Fluorimetric determination of levoprotiline in human plasma after thin-layer chromatographic or high performance liquid chromatographic separation.
The quantitative determination of the new antidepressant drug levoprotiline, the R-(-)-enantiomer of oxa-protiline (a-[methylamino)methyl)-9,10-ethanoanthracene-9(10H)-ethanol), in human biological material is described. Analysis is performed by alkaline extraction with n-heptane-isopropanol, subsequent fluorescence derivatisation with NBD chloride (4-chloro-7-nitrobenzofurazan), thin layer or high performance liquid chromatography, and fluorimetric measurement of the derivatisation product (lambda max ex. = 470 nm, lambda max em. = 525 nm). The sensitivity of the procedure (detection limit less than 1 ng/ml) permits the performance of pharmacokinetic studies after therapeutic doses.
Pharmakologisches Institut für Naturwissenschaftler, Johann Wolfgang Goethe-Universität, Frankfurt/Main, Fed. Rep. of Germany.
C
C
Horne
H
H
Spahn
E
E
Mutschler
D000873:Anthracenes / Q000097:blood*; D000928:Antidepressive Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D006801:Humans; D008376:Maprotiline / Q000031:analogs & derivatives / Q000097:blood*; D013050:Spectrometry, Fluorescence
D000873:Anthracenes; D000928:Antidepressive Agents; D008376:Maprotiline; C027299:hydroxymaprotilin